Haisco Pharmaceutical Group Co (SZSE:002653) 3-Year EBITDA Growth Rate : -12.10% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co 3-Year EBITDA Growth Rate?

Haisco Pharmaceutical Group Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.09.

During the past 12 months, Haisco Pharmaceutical Group Co's average EBITDA Per Share Growth Rate was -11.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -12.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 3.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Haisco Pharmaceutical Group Co was 33.20% per year. The lowest was -14.80% per year. And the median was 5.50% per year.

Competitive Comparison of Haisco Pharmaceutical Group Co's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Haisco Pharmaceutical Group Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haisco Pharmaceutical Group Co's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haisco Pharmaceutical Group Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Haisco Pharmaceutical Group Co's 3-Year EBITDA Growth Rate falls into.

Haisco Pharmaceutical Group Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Haisco Pharmaceutical Group Co (SZSE:002653) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Haisco Pharmaceutical Group Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Haisco Pharmaceutical Group Co (SZSE:002653) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000

Website

http://www.haisco.com

Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.

Haisco Pharmaceutical Group Co (SZSE:002653) Headlines

No Headlines